Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASH 2015

5 - 7 Dec 2015

TBC, Orlando, United States of America

ASH 2015: Blinatumomab data shows benefit in Phase 2 trial in ALL patients with persistent or recurrent minimal residual disease

ASH 2015: Blinatumomab data shows benefit in Phase 2 trial in ALL patients with persistent or recurrent minimal...

ASH 2015: Chronic lymphocytic leukaemia mutations suggest new uses of existing cancer drugs

ASH 2015: Chronic lymphocytic leukaemia mutations suggest new uses of existing cancer drugs

ASH 2015: Personalising cancer treatment through computer simulations and lab work

ASH 2015: Personalising cancer treatment through computer simulations and lab work

ASH 2015: New vaccine strategy better protects high-risk cancer patients from flu

ASH 2015: New vaccine strategy better protects high-risk cancer patients from flu

$ASH 2015: Results from phase 2 study for treatment of relapsed or refractory hodgkin lymphoma following autologous stem cell transplantation$

ASH 2015: Results from phase 2 study for treatment of relapsed or refractory hodgkin lymphoma following autologous...

ASH 2015: Study finds new use for rituximab in acute leukaemia

ASH 2015: Study finds new use for rituximab in acute leukaemia

ASH 2015: First targeted therapy for genetically defined subset of patients with acute myeloid leukaemia significantly improves survival

ASH 2015: First targeted therapy for genetically defined subset of patients with acute myeloid leukaemia...

ASH 2015: Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia shows promise

ASH 2015: Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia shows promise

ASH 2015: Combination therapy with idelalisib better prevents disease progression in relapsed or treatment-resistant chronic lymphocytic leukaemia than current regimen

ASH 2015: Combination therapy with idelalisib better prevents disease progression in relapsed or treatment...

ASH 2015: Study underscores promise of targeted therapies as first-line approach for patients with chronic lymphocytic leukaemia

ASH 2015: Study underscores promise of targeted therapies as first-line approach for patients with chronic...

ASH 2015: First targeted therapy for multiple myeloma effective against hard-to-treat disease

ASH 2015: First targeted therapy for multiple myeloma effective against hard-to-treat disease

ASH 2015: Ixazomib for relapsed and treatment-resistant multiple myeloma

ASH 2015: Ixazomib for relapsed and treatment-resistant multiple myeloma

ASH 2015: Study suggests warfarin is acceptable for long-term treatment of cancer-associated thrombosis

ASH 2015: Study suggests warfarin is acceptable for long-term treatment of cancer-associated thrombosis

ASH 2015: Whole exome sequencing finds genes associated with autoimmune platelet disorder in children

ASH 2015: Whole exome sequencing finds genes associated with autoimmune platelet disorder in children

ASH 2015: Researchers identify children most at risk of over-reporting adherence to at-home chemotherapy regimen

ASH 2015: Researchers identify children most at risk of over-reporting adherence to at-home chemotherapy regimen

ASH 2015: Research provides guidance for anticoagulation management in the setting of thrombocytopenia in cancer patients

ASH 2015: Research provides guidance for anticoagulation management in the setting of thrombocytopenia in cancer...

ASH 2015: Genetic variant signifies higher risk for avascular necrosis in children with acute leukaemia

ASH 2015: Genetic variant signifies higher risk for avascular necrosis in children with acute leukaemia

ASH 2015: Classification system based on cytogenetics and treatment response identifies leukaemia patients with high risk clinical features but outstanding outcomes

ASH 2015: Classification system based on cytogenetics and treatment response identifies leukaemia patients with...

ASH 2015: Genetic variants for increased risk of osteonecrosis in paediatric acute lymphocytic leukaemia identified

ASH 2015: Genetic variants for increased risk of osteonecrosis in paediatric acute lymphocytic leukaemia identified

$ASH 2015: Carfilzomib superior to bortezomib in relapsed and refractory multiple myeloma$

ASH 2015: Carfilzomib superior to bortezomib in relapsed and refractory multiple myeloma

ASH 2015: Engineered donor T cells may eradicate progressive disease after stem cell transplant

ASH 2015: Engineered donor T cells may eradicate progressive disease after stem cell transplant

ASH 2015: Engineered cells to target multiple myeloma shows early promise

ASH 2015: Engineered cells to target multiple myeloma shows early promise

More from ecancer